×
ResMed Cash on Hand 2010-2024 | RMD
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
ResMed cash on hand for the quarter ending September 30, 2024 was
$0.426B
, a
103.9% increase
year-over-year.
ResMed cash on hand for 2024 was
$0.238B
, a
4.59% increase
from 2023.
ResMed cash on hand for 2023 was
$0.228B
, a
16.74% decline
from 2022.
ResMed cash on hand for 2022 was
$0.274B
, a
7.3% decline
from 2021.
View More
ResMed Cash on Hand 2010-2024 | RMD
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
ResMed cash on hand for 2024 was
$0.238B
, a
4.59% increase
from 2023.
ResMed cash on hand for 2023 was
$0.228B
, a
16.74% decline
from 2022.
ResMed cash on hand for 2022 was
$0.274B
, a
7.3% decline
from 2021.
Related Stocks
Company Name
Market
Cap
Abbott Laboratories (ABT)
$203.2B
Stryker (SYK)
$148.2B
Boston Scientific (BSX)
$133.1B
EssilorLuxottica (ESLOY)
$113.5B
Medtronic (MDT)
$109B
Haleon (HLN)
$42.9B
Lonza Group Ag (LZAGY)
$42.1B
GE HealthCare Technologies (GEHC)
$37.7B
Terumo (TRUMY)
$29.2B
Koninklijke Philips (PHG)
$24.4B
Zimmer Biomet Holdings (ZBH)
$22.1B
Insulet (PODD)
$18.4B
Baxter (BAX)
$16.6B
Smith & Nephew SNATS (SNN)
$11.2B
BellRing Brands (BRBR)
$9.5B
Bio-Rad Laboratories (BIO)
$9B
Demant (WILYY)
$8.3B
Lantheus Holdings (LNTH)
$5.5B
TG Therapeutics (TGTX)
$4.7B
Haemonetics (HAE)
$4.3B
ICU Medical (ICUI)
$4.2B
Prestige Consumer Healthcare (PBH)
$4.1B
Perrigo (PRGO)
$3.7B
Envista Holdings (NVST)
$3.5B
Neogen (NEOG)
$3.3B
Agios Pharmaceuticals (AGIO)
$3.1B
Shandong Weigao Medical Polymer (SHWGF)
$3B
GN Store Nord (GNNDY)
$2.8B
QuidelOrtho (QDEL)
$2.6B
Warby Parker (WRBY)
$2.3B